SG11201407349UA - Proliposomal testosterone formulations - Google Patents
Proliposomal testosterone formulationsInfo
- Publication number
- SG11201407349UA SG11201407349UA SG11201407349UA SG11201407349UA SG11201407349UA SG 11201407349U A SG11201407349U A SG 11201407349UA SG 11201407349U A SG11201407349U A SG 11201407349UA SG 11201407349U A SG11201407349U A SG 11201407349UA SG 11201407349U A SG11201407349U A SG 11201407349UA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- iii
- llll
- drive
- testosterone
- Prior art date
Links
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 title abstract 8
- 229960003604 testosterone Drugs 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 3
- 238000009472 formulation Methods 0.000 title abstract 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- 239000006185 dispersion Substances 0.000 abstract 2
- 239000000843 powder Substances 0.000 abstract 2
- 241000124033 Salix Species 0.000 abstract 1
- 238000009165 androgen replacement therapy Methods 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000006186 oral dosage form Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 150000003904 phospholipids Chemical class 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1277—Preparation processes; Proliposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Reproductive Health (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
Abstract
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 14 November 2013 (14.11.2013) WIPOIPCT (10) International Publication Number WO 2013/170012 A2 (51) International Patent Classification: A61K 9/48 (2006.01) (21) International Application Number: PCT/US2013/040325 (22) International Filing Date: 9 May 2013 (09.05.2013) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 61/644,996 9 May 2012 (09.05.2012) US (71) Applicants: WESTERN UNIVERSITY OF HEALTH SCIENCES [US/US]; 309 E. Second Street, Pomona, CA 91766 (US). TESORX PHARMA, LLC [US/US]; 900 Willow Rd„ Ste. B, Menlo Park, CA 94025 (US). (72) Inventors; and (71) Applicants (for US only): BETAGERI, Guru, V. [US/US]; 17325 Eastview Drive, Chino Hills, CA 91709 (US). THIRUCOTE, Ramachandran [US/US]; 397 Fletcher Drive, Atherton, CA 94027 (US). KADAJJI, Veeran, Gowda [IN/US]; 11030 Moorpark St, Apt. 18, North Hollywood, CA 91602 (US). (74) Agent: LINDEMAN, Jeffrey, A.; J.A. Lindeman & Co., PLLC, 3190 Fairview Park Drive, Suite 480, Falls Church, VA 22042 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, [Continued on next page] (54) Title: PROLIPOSOMAL TESTOSTERONE FORMULATIONS 600.00 500.00 10 12 14 16 18 20 22 24 Time in hours (57) Abstract: Novel testosterone for mulations are disclosed where testoster one incorporated into phospholipid/ is a cholesterol system to produce a pro li posomal powder dispersion. The pro li posomal powder dispersions of the in vention may be formulated with phamarceutically acceptable excipients to form pharmaceutical compositions. Enterically coated oral dosage forms are disclosed as are methods of treat ment for testosterone replacement ther apy. FIG. 24 wo 2013/170012 A21II llll IIII III Hill lllll III III III 111 II III! Hill llll 111 lllllll llll 111 llll TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, Published: EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG). — without international search report and to be republished upon receipt of that report (Rule 48.2(g))
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261644996P | 2012-05-09 | 2012-05-09 | |
| PCT/US2013/040325 WO2013170012A2 (en) | 2012-05-09 | 2013-05-09 | Proliposomal testosterone formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201407349UA true SG11201407349UA (en) | 2014-12-30 |
Family
ID=49551459
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201702240TA SG10201702240TA (en) | 2012-05-09 | 2013-05-09 | Proliposomal testosterone formulations |
| SG11201407349UA SG11201407349UA (en) | 2012-05-09 | 2013-05-09 | Proliposomal testosterone formulations |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201702240TA SG10201702240TA (en) | 2012-05-09 | 2013-05-09 | Proliposomal testosterone formulations |
Country Status (32)
| Country | Link |
|---|---|
| US (5) | US8957053B2 (en) |
| EP (1) | EP2846781B1 (en) |
| JP (3) | JP6055088B2 (en) |
| KR (1) | KR20150032939A (en) |
| CN (2) | CN108096192A (en) |
| AP (1) | AP2014008099A0 (en) |
| AR (1) | AR091006A1 (en) |
| AU (2) | AU2013259509B2 (en) |
| BR (1) | BR112014027942A2 (en) |
| CA (1) | CA2872779A1 (en) |
| CL (1) | CL2014003034A1 (en) |
| CO (1) | CO7240373A2 (en) |
| CR (1) | CR20140561A (en) |
| DO (1) | DOP2015000026A (en) |
| EA (2) | EA201791738A1 (en) |
| EC (1) | ECSP14030572A (en) |
| GE (1) | GEP201706754B (en) |
| HK (2) | HK1210409A1 (en) |
| IL (1) | IL235464B (en) |
| IN (1) | IN2014DN10383A (en) |
| MA (1) | MA37610B1 (en) |
| MX (1) | MX367123B (en) |
| MY (1) | MY175305A (en) |
| NZ (2) | NZ702634A (en) |
| PE (1) | PE20150203A1 (en) |
| PH (1) | PH12014502498A1 (en) |
| SG (2) | SG10201702240TA (en) |
| TN (1) | TN2014000467A1 (en) |
| TW (2) | TWI664982B (en) |
| UA (1) | UA115058C2 (en) |
| WO (1) | WO2013170012A2 (en) |
| ZA (2) | ZA201408996B (en) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10213440B2 (en) | 2014-08-20 | 2019-02-26 | Professional Compounding Centers Of America (Pcca) | Oral transmucosal pharmaceutical compositions including testosterone and an aromatase inhibitor |
| KR101682821B1 (en) | 2015-07-21 | 2016-12-06 | 서울대학교산학협력단 | Preparing method of proliposomes |
| MX2018008267A (en) * | 2016-01-07 | 2018-09-28 | Univ Western Health Sciences | Formulations for treating bladder cancer. |
| EP3399965A4 (en) * | 2016-01-08 | 2019-08-21 | Western University Of Health Sciences | PROLIPOSOMAL TESTOSTERONE UNDECANOATE FORMULATIONS |
| KR102574139B1 (en) | 2016-07-07 | 2023-09-05 | 삼성전자주식회사 | Method and Apparatus for changing Mode of Wireless Charging |
| KR20190084284A (en) | 2016-11-11 | 2019-07-16 | 웨스턴 유니버시티 오브 헬스 사이언시스 | Treatment of upper urinary tract carcinoma |
| IL274579B2 (en) | 2017-11-17 | 2025-04-01 | Evonik Operations Gmbh | Process for preparing a coated hard shell capsule |
| US10716774B1 (en) | 2018-01-05 | 2020-07-21 | Yale Pharmaceuticals LLC | Pharmaceutical compositions containing isotretinoin with improved dissolution profile and enhanced stability |
| US12150945B2 (en) | 2018-07-20 | 2024-11-26 | Lipocine Inc. | Liver disease |
| WO2020069450A1 (en) * | 2018-09-28 | 2020-04-02 | Joel Studin | Transpore delivery of drugs and uses thereof |
| WO2020229178A1 (en) * | 2019-05-15 | 2020-11-19 | Evonik Operations Gmbh | Process for preparing filled hard-shell capsules with (meth)acrylate copolymer based coatings with a capsule-filling machine |
| CN120346175A (en) * | 2019-05-15 | 2025-07-22 | 赢创运营有限公司 | Method for preparing filled hard shell capsules with cellulose or starch based coating using capsule filling machine |
| AU2020329775A1 (en) * | 2019-08-09 | 2022-02-24 | Tesorx Pharma, Llc | Proliposomal testosterone undecanoate formulations |
| CN110747271B (en) * | 2019-12-02 | 2023-07-18 | 延边大学 | The markers of vascular injury-restenosis degree after PCI |
| JP6945874B2 (en) * | 2019-12-24 | 2021-10-06 | 一般財団法人バイオダイナミックス研究所 | Pharmaceutical composition for oral administration |
| CN111840240A (en) * | 2020-05-29 | 2020-10-30 | 仁和堂药业有限公司 | Finasteride preparation and application thereof |
| CN112121003B (en) * | 2020-09-29 | 2022-02-01 | 江苏集萃新型药物制剂技术研究所有限公司 | Drug-carrying material of sustained-release preparation, composition of drug-carrying material, sustained-release preparation and preparation method of sustained-release preparation |
| WO2022245650A1 (en) * | 2021-05-19 | 2022-11-24 | Alberto Paz | Orally administered compositions for cancer treatment |
| CN114668719B (en) * | 2022-02-21 | 2023-06-16 | 广东食品药品职业学院 | Dihydrotestosterone suspension and lyophilized powder thereof and preparation method thereof |
| WO2024056062A1 (en) * | 2022-09-16 | 2024-03-21 | 长春金赛药业有限责任公司 | Steroid hormone-phospholipid composition and preparation method therefor |
| CN117018211B (en) * | 2023-07-31 | 2025-09-09 | 沈阳药科大学 | Testosterone-cholesterol prodrug and preparation method and application thereof |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4744989A (en) | 1984-02-08 | 1988-05-17 | E. R. Squibb & Sons, Inc. | Method of preparing liposomes and products produced thereby |
| US5002936A (en) | 1985-04-12 | 1991-03-26 | Seymour Lieberman | Lipophilic complexes of pharmacologically active inorganic mineral acid esters of organic compounds |
| US5049388A (en) * | 1986-11-06 | 1991-09-17 | Research Development Foundation | Small particle aerosol liposome and liposome-drug combinations for medical use |
| CA1337397C (en) | 1988-09-29 | 1995-10-24 | Hideo Nakajima | Emulsified composition |
| IE904098A1 (en) | 1989-11-13 | 1991-05-22 | Nova Pharm Corp | Lipospheres for controlled delivery of substances |
| US20040175417A1 (en) | 1990-10-19 | 2004-09-09 | Gilead Sciences, Inc. | Amphotericin B liposome preparation |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| JP3017906B2 (en) | 1993-10-08 | 2000-03-13 | 信越化学工業株式会社 | Enteric coating agent dispersion |
| US6214375B1 (en) | 1996-07-16 | 2001-04-10 | Generex Pharmaceuticals, Inc. | Phospholipid formulations |
| US6506783B1 (en) | 1997-05-16 | 2003-01-14 | The Procter & Gamble Company | Cancer treatments and pharmaceutical compositions therefor |
| US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
| US20030236236A1 (en) | 1999-06-30 | 2003-12-25 | Feng-Jing Chen | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
| US6761901B1 (en) | 2000-05-02 | 2004-07-13 | Enzrel Inc. | Liposome drug delivery |
| US6858596B2 (en) * | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivative |
| WO2002051426A2 (en) | 2000-12-22 | 2002-07-04 | A Glenn Braswell | Compositions and methods for treating sexual dysfunction, enhancing sexual function, increasing testosterone levels, and improving muscle strength and mass |
| US6534080B2 (en) | 2001-02-12 | 2003-03-18 | Super Gen, Inc. | Method for administering camptothecins via injection of pharmaceutical composition comprising coated particles of a camptothecin |
| US6759058B1 (en) * | 2001-04-25 | 2004-07-06 | Western Center For Drug Development College Of Pharmacy Western University Of Health Sciences | Enteric-coated proliposomal formulations for poorly water soluble drugs |
| US8658202B2 (en) * | 2001-04-25 | 2014-02-25 | Western University Of Health Sciences | Coated drug delivery formulations |
| US20040115226A1 (en) | 2002-12-12 | 2004-06-17 | Wenji Li | Free-flowing solid formulations with improved bio-availability of poorly water soluble drugs and process for making the same |
| JO2505B1 (en) * | 2003-03-14 | 2009-10-05 | باير شيرنغ فارما اكتنجيسيلشافت | method and pharmaceutical compositions for reliable achievements of acceptable serum testosterone levels |
| EP1624857A2 (en) | 2003-05-12 | 2006-02-15 | Novosom AG | Injectable depots consisting of liposomal aggregates for the delivery of active substances |
| CA2544627A1 (en) | 2003-11-05 | 2005-05-19 | Elan Pharma International Ltd. | Nanoparticulate compositions having a peptide as a surface stabilizer |
| WO2006012502A2 (en) | 2004-07-23 | 2006-02-02 | Rigel Pharmaceuticals, Inc. | Formulation of insoluble small molecule therapeutics in lipid-based carriers |
| WO2006062506A1 (en) | 2004-12-03 | 2006-06-15 | Enzrel, Inc. | Chitosan-coated liposome drug delivery of antioxidant or anti-inflammatory compounds |
| EP1959961A2 (en) | 2005-12-06 | 2008-08-27 | Rigel Pharmaceuticals, Inc. | Formulation of insoluble small molecule therapeutics in lipid-based carriers |
| US20070154403A1 (en) | 2006-01-05 | 2007-07-05 | Thomas Skold | Oral, Pulmonary and Transmucosal Delivery Composition |
| NZ572308A (en) | 2006-03-30 | 2011-09-30 | Univ New York State Res Found | Compositions of less immunogenic and long-circulating protein-lipid complexes |
| CA2681302C (en) * | 2007-03-19 | 2013-07-23 | Dhiraj Khattar | Proliposomal and liposomal compositions of poorly water-soluble compounds |
| US11304960B2 (en) * | 2009-01-08 | 2022-04-19 | Chandrashekar Giliyar | Steroidal compositions |
| JP2013540827A (en) * | 2010-10-29 | 2013-11-07 | ウエスタン ユニバーシティ オブ ヘルス サイエンシズ | Three-mixed preparation |
| US20120148675A1 (en) | 2010-12-10 | 2012-06-14 | Basawaraj Chickmath | Testosterone undecanoate compositions |
| CA2845118A1 (en) | 2011-08-18 | 2013-02-21 | Monosol Rx, Llc | Steroid hormone delivery systems and methods of preparing the same |
-
2013
- 2013-05-09 TW TW106138648A patent/TWI664982B/en not_active IP Right Cessation
- 2013-05-09 CA CA2872779A patent/CA2872779A1/en not_active Abandoned
- 2013-05-09 KR KR1020147034548A patent/KR20150032939A/en not_active Ceased
- 2013-05-09 AU AU2013259509A patent/AU2013259509B2/en not_active Ceased
- 2013-05-09 EP EP13787438.4A patent/EP2846781B1/en active Active
- 2013-05-09 WO PCT/US2013/040325 patent/WO2013170012A2/en not_active Ceased
- 2013-05-09 PE PE2014002002A patent/PE20150203A1/en active IP Right Grant
- 2013-05-09 SG SG10201702240TA patent/SG10201702240TA/en unknown
- 2013-05-09 GE GEAP201313659A patent/GEP201706754B/en unknown
- 2013-05-09 EA EA201791738A patent/EA201791738A1/en unknown
- 2013-05-09 JP JP2015511696A patent/JP6055088B2/en not_active Expired - Fee Related
- 2013-05-09 EA EA201492047A patent/EA028809B1/en not_active IP Right Cessation
- 2013-05-09 AP AP2014008099A patent/AP2014008099A0/en unknown
- 2013-05-09 NZ NZ702634A patent/NZ702634A/en not_active IP Right Cessation
- 2013-05-09 IN IN10383DEN2014 patent/IN2014DN10383A/en unknown
- 2013-05-09 TW TW102116691A patent/TWI614035B/en not_active IP Right Cessation
- 2013-05-09 CN CN201810024730.3A patent/CN108096192A/en active Pending
- 2013-05-09 NZ NZ721900A patent/NZ721900A/en not_active IP Right Cessation
- 2013-05-09 HK HK15109133.2A patent/HK1210409A1/en unknown
- 2013-05-09 MA MA37610A patent/MA37610B1/en unknown
- 2013-05-09 CN CN201380032890.8A patent/CN104780914B/en not_active Expired - Fee Related
- 2013-05-09 SG SG11201407349UA patent/SG11201407349UA/en unknown
- 2013-05-09 AR ARP130101616A patent/AR091006A1/en unknown
- 2013-05-09 MX MX2014013450A patent/MX367123B/en active IP Right Grant
- 2013-05-09 BR BR112014027942A patent/BR112014027942A2/en active Search and Examination
- 2013-05-09 MY MYPI2014703308A patent/MY175305A/en unknown
- 2013-09-05 UA UAA201413186A patent/UA115058C2/en unknown
-
2014
- 2014-01-07 US US14/149,227 patent/US8957053B2/en not_active Expired - Fee Related
- 2014-11-02 IL IL235464A patent/IL235464B/en active IP Right Grant
- 2014-11-04 TN TN2014000467A patent/TN2014000467A1/en unknown
- 2014-11-07 PH PH12014502498A patent/PH12014502498A1/en unknown
- 2014-11-07 CL CL2014003034A patent/CL2014003034A1/en unknown
- 2014-12-04 CR CR20140561A patent/CR20140561A/en unknown
- 2014-12-08 ZA ZA2014/08996A patent/ZA201408996B/en unknown
- 2014-12-09 CO CO14270756A patent/CO7240373A2/en unknown
- 2014-12-09 EC ECIEPI201430572A patent/ECSP14030572A/en unknown
-
2015
- 2015-01-26 US US14/604,985 patent/US9445995B2/en not_active Expired - Fee Related
- 2015-02-12 DO DO2015000026A patent/DOP2015000026A/en unknown
- 2015-12-22 ZA ZA2015/09340A patent/ZA201509340B/en unknown
-
2016
- 2016-08-29 US US15/250,169 patent/US9623033B2/en not_active Expired - Fee Related
- 2016-09-19 US US15/268,917 patent/US9844557B2/en not_active Expired - Fee Related
- 2016-12-01 JP JP2016234097A patent/JP6208842B2/en not_active Expired - Fee Related
-
2017
- 2017-09-07 JP JP2017172142A patent/JP6368020B2/en not_active Expired - Fee Related
- 2017-11-29 US US15/825,530 patent/US20180303850A1/en not_active Abandoned
- 2017-12-07 AU AU2017272249A patent/AU2017272249B2/en not_active Ceased
-
2018
- 2018-11-23 HK HK18114995.6A patent/HK1255929A1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201407349UA (en) | Proliposomal testosterone formulations | |
| SG11201807660QA (en) | Cyclic di-nucleotide compounds and methods of use | |
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201408261UA (en) | Syringe | |
| SG11201803906PA (en) | Control of cellular redox levels | |
| SG11201407340YA (en) | Treatment of myelosuppression | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201804170RA (en) | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders | |
| SG11201408769QA (en) | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | |
| SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
| SG11201803686UA (en) | Prodrugs of a jak inhibitor compound for treatment of gastrointestinal inflammatory disease | |
| SG11201805645QA (en) | Lsd1 inhibitors | |
| SG11201803701YA (en) | Methods and compositions for gene editing in hematopoietic stem cells | |
| SG11201907023UA (en) | Method of reducing neutropenia | |
| SG11201804901WA (en) | Compounds for the treatment of cancer and inflammatory disease | |
| SG11201808422QA (en) | Gene therapy for treating hemophilia a | |
| SG11201408770RA (en) | Compounds and therapeutic uses thereof | |
| SG11201408251SA (en) | A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota | |
| SG11201808003RA (en) | Bromodomain inhibitors | |
| SG11201907889YA (en) | Glycan-interacting compounds and methods of use | |
| SG11201909495PA (en) | Combination cancer immunotherapy with pentaaza macrocyclic ring complex | |
| SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
| SG11201806583XA (en) | Compositions containing tucaresol or its analogs | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof |